Key result
AAV-delivered mutant ACE2 reduces pulmonary artery pressure and vascular remodeling in hypoxic pulmonary hypertension.
Why the study?
NEDD4L drives pulmonary hypertension by promoting the ubiquitination and degradation of ACE2, but whether this regulation occurs at a specific residue and whether targeting that residue is therapeutically useful had not been determined.
Does blocking NEDD4L-mediated ACE2 ubiquitination via the K788R mutation attenuate hypoxia-induced pulmonary hypertension and vascular remodeling in ACE2-knockout rats?
Does blocking NEDD4L-mediated ACE2 ubiquitination via the K788R mutation attenuate hypoxia-induced pulmonary hypertension and vascular remodeling in ACE2-knockout rats?
Answers are grounded in this paper and cite their sources.
Selectively blocking NEDD4L-mediated ACE2 ubiquitination at lysine 788 stabilizes ACE2 against degradation and attenuates experimental hypoxia-induced pulmonary hypertension in rats, identifying a potential site-specific therapeutic target.
Background We previously showed that neural precursor cell-expressed developmentally down-regulated gene 4-like (NEDD4L), an E3 ubiquitin ligase, drives pulmonary hypertension by promoting the ubiquitination and subsequent degradation of angiotensin-converting enzyme 2 (ACE2). Whether this regulation occurs at a specific residue, and whether targeting that residue is therapeutically useful, had not been determined. Methods Based on bioinformatic prediction combined with previously validated ubiquitin-acceptor lysines in the intracellular C-terminal tail of ACE2, we substituted lysine 788 with arginine to generate the K788R ACE2 mutant. Co-immunoprecipitation (co-IP) in pulmonary artery smooth muscle cells (PASMCs) was used to examine the interaction of NEDD4L with wild-type or K788R ACE2. For in vivo experiments, ACE2-knockout rats were given adeno-associated virus (AAV) carrying either wild-type or K788R ACE2, followed by 4 weeks of chronic hypoxia (10% O₂). Echocardiography, blood-gas analysis, histology, TUNEL staining, quantitative PCR, and Western blotting were performed to evaluate pulmonary artery pressure, oxygenation, pulmonary vascular remodeling, apoptosis, and gene and protein expression. Results Under both normoxic and hypoxic conditions, the K788R mutation greatly weakened the NEDD4L–ACE2 association in PASMCs and in rat lung tissue, although wild-type and mutant ACE2 were expressed at comparable levels. Relative to ACE2-knockout rats reconstituted with wild-type ACE2, those reconstituted with K788R ACE2 showed markedly lower pulmonary artery pressure, less pulmonary arteriolar muscularization and medial wall thickening, a higher oxygenation index, and reduced hypoxia-induced apoptosis in lung tissue. Conclusion These findings establish K788, a validated ubiquitin-acceptor lysine in the intracellular tail of ACE2, as an essential residue for the NEDD4L–ACE2 interaction, and they show that selectively blocking ACE2 ubiquitination at this single site alleviates hypoxia-induced pulmonary hypertension in rats. Intervention at the NEDD4L–ACE2 axis through K788 may thus offer a precision therapeutic approach that stabilizes ACE2 while sparing global NEDD4L function.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied Hypoxia-induced pulmonary hypertension (preclinical rat model) (n=18). AAV6 encoding K788R-mutated ACE2 (AAV-MUT) vs. AAV6 encoding wild-type ACE2 (AAV-WT) and control AAV in wild-type rats (NC) was evaluated on Estimated pulmonary artery pressure, oxygenation index, and pulmonary vascular remodeling (arteriolar muscularization and medial wall thickness ratio) (p=<0.01). AAV-mediated delivery of K788R-mutated ACE2 disrupted NEDD4L-ACE2 binding and significantly reduced pulmonary artery pressure, vascular remodeling, and lung apoptosis in hypoxic ACE2-knockout rats.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: